Current Gastroenterology Reports

, Volume 10, Issue 3, pp 324–331 | Cite as

Step-up and step-down approaches to treatment of gastroesophageal reflux disease in children

  • Eric HassallEmail author


The single biggest change in the approach to treating pediatric gastroesophageal reflux disease (GERD) in recent years has been the empiric use of proton pump inhibitors (PPIs) for symptoms suspected to be those of GERD. In other words, PPIs have been used increasingly as a first-line concurrent diagnostic test and treatment before any investigation. Although this approach is useful for some patients, there are a number of caveats about its application to children. In general, these caveats are related to age per se (eg, infancy) and to age-related symptoms and severity of GERD itself. The most important caveats relate to the prescription of empiric PPI therapy in infants—which generally is to be avoided—and to how PPIs are used in older children—specifically, the advisability of empiric trials being of limited duration. Even in children with proven reflux esophagitis, GERD is not chronic and relapsing in all; thus, trials of therapy withdrawal are warranted. In light of many factors, including the burgeoning literature on potential risks of infections in acid-suppressed children and adults, caution with dose and duration of acid-suppressive drugs in children is urged. The role of antireflux surgery is also mentioned.


Omeprazole Esophagitis Lansoprazole Esomeprazole Erosive Esophagitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    McGuigan JE: Treatment of gastroesophageal reflux disease: to step or not to step. Am J Gastroenterol 2001, 96:1679–1681.PubMedCrossRefGoogle Scholar
  2. 2.
    Martin AJ, Pratt N, Kennedy JD, et al.: Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 2002, 109:1061–1067.PubMedCrossRefGoogle Scholar
  3. 3.
    Nelson SP, Chen EH, Syniar GM, Christoffel KK: Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997, 151:569–572.PubMedGoogle Scholar
  4. 4.
    Vakil N, van Zanten SV, Kahrilas P, et al.: The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006, 101:1900–1920; quiz 1943.PubMedCrossRefGoogle Scholar
  5. 5.
    Barr RG: Colic and crying syndromes in infants. Pediatrics 1998, 102:1282–1286.PubMedGoogle Scholar
  6. 6.
    Hassall E: Talk is cheap, often effective: symptoms in infants often respond to non-pharmacologic measures. J Pediatr 2008, 152:301–303.PubMedCrossRefGoogle Scholar
  7. 7.
    Orenstein S, McGowan J: Efficacy of conservative therapy as taught in the primary care setting for symptoms suggesting infant gastroesophageal reflux. J Pediatr 2008, 152:310–314.PubMedCrossRefGoogle Scholar
  8. 8.
    Sutphen JL: Is it colic or is it gastroesophageal reflux? J Pediatr Gastroenterol Nutr 2001, 33:110–111.PubMedCrossRefGoogle Scholar
  9. 9.
    Hassall E: Co-morbidities in childhood Barrett’s esophagus. J Pediatr Gastroenterol Nutr 1997, 25:255–260.PubMedCrossRefGoogle Scholar
  10. 10.
    Hassall E: Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr 2005, 146:S3–S12.PubMedCrossRefGoogle Scholar
  11. 11.
    Rudolph CD, Mazur LJ, Liptak GS, et al.: Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001, 32(Suppl 2):S1–S31.PubMedCrossRefGoogle Scholar
  12. 12.
    Vandenplas Y, Hassall E: Mechanisms of gastroesophageal reflux and gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002, 35:119–136.PubMedCrossRefGoogle Scholar
  13. 13.
    Hassall E, Israel DM, Davidson AG, Wong LT: Barrett’s esophagus in children with cystic fibrosis: not a coincidental association. Am J Gastroenterol 1993, 88:1934–1938.PubMedGoogle Scholar
  14. 14.
    Hassall E, Kerr W, El-Serag HB: Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007, 150:262–267.PubMedCrossRefGoogle Scholar
  15. 15.
    Hassall E: Barrett’s esophagus: new definitions and approaches in children. J Pediatr Gastroenterol Nutr 1993, 16:345–364.PubMedCrossRefGoogle Scholar
  16. 16.
    Qualman SJ, Murray RD, McClung HJ, Lucas J: Intestinal metaplasia is age related in Barrett’s esophagus. Arch Pathol Lab Med 1990, 114:1236–1240.PubMedGoogle Scholar
  17. 17.
    Fitzgerald RC: Barrett’s oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation? Gut 2005, 54(Suppl 1):i21–i26.PubMedCrossRefGoogle Scholar
  18. 18.
    Hassall E, Dimmick JE, Magee JF: Adenocarcinoma in childhood Barrett’s esophagus: case documentation and the need for surveillance in children. Am J Gastroenterol 1993, 88:282–288.PubMedGoogle Scholar
  19. 19.
    Hassall E: Cardia-type mucosa as an esophageal metaplastic condition in children: Barrett’s esophagus, gastric mucosapositive. J Pediatr Gastroenterol Nutr 2008 (in press).Google Scholar
  20. 20.
    El-Serag HB, Gilger M, Kuebeler M, Rabeneck L: Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. Gastroenterology 2001, 121:1294–1299.PubMedCrossRefGoogle Scholar
  21. 21.
    Khoshoo V, Le T, Haydel RM Jr, et al.: Role of gastroesophageal reflux in older children with persistent asthma. Chest 2003, 123:1008–1013.PubMedCrossRefGoogle Scholar
  22. 22.
    Amin RS: Gastroesophageal reflux and infant apnea. J Pediatr 2000, 137:298–300.PubMedCrossRefGoogle Scholar
  23. 23.
    Poets CF: Gastroesophageal reflux: a critical review of its role in preterm infants. Pediatrics 2004, 113:e128–e132.PubMedCrossRefGoogle Scholar
  24. 24.
    El-Serag HB: Temporal trends in new and recurrent esophageal strictures in Department of Veterans Affairs. Am J Gastroenterol 2006, 101:1727–1733.PubMedCrossRefGoogle Scholar
  25. 25.
    Hassall E: Outcomes of fundoplication: causes for concern, newer options. Arch Dis Child 2005, 90:1047–1052.PubMedCrossRefGoogle Scholar
  26. 26.
    Gerson LB: A little weight gain, how much gastroesophageal reflux disease? Gastroenterology 2006, 131:1644–1646; discussion 1646.PubMedCrossRefGoogle Scholar
  27. 27.
    Orenstein SR, Gremse DA, Pantaleon CD, et al.: Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Clin Ther 2005, 27:472–483.PubMedCrossRefGoogle Scholar
  28. 28.
    Orenstein SR, Shalaby TM, Devandry SN, et al.: Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther 2003, 17:1097–1107.PubMedCrossRefGoogle Scholar
  29. 29.
    Simeone D, Caria MC, Miele E, Staiano A: Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. J Pediatr Gastroenterol Nutr 1997, 25:51–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Orenstein SR, Blumer JL, Faessel HM, et al.: Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2002, 16:899–907.PubMedCrossRefGoogle Scholar
  31. 31.
    Hyman PE, Garvey TQ 3rd, Abrams CE: Tolerance to intravenous ranitidine. J Pediatr 1987, 110:794–796.PubMedCrossRefGoogle Scholar
  32. 32.
    Nwokolo CU, Smith JT, Gavey C, et al.: Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990, 4(Suppl 1):29–45.PubMedGoogle Scholar
  33. 33.
    Andersson T, Hassall E, Lundborg P, et al.: Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 2000, 95:3101–3106.PubMedCrossRefGoogle Scholar
  34. 34.
    Fiedorek S, Tolia V, Gold BD, et al.: Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2005, 40:319–327.PubMedCrossRefGoogle Scholar
  35. 35.
    Gremse D, Winter H, Tolia V, et al.: Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002, 35(Suppl 4):S319–S326.PubMedGoogle Scholar
  36. 36.
    Gunasekaran TS, Hassall EG: Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993, 123:148–154.PubMedCrossRefGoogle Scholar
  37. 37.
    Hassall E, Israel D, Shepherd R, et al.: Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000, 137:800–807.PubMedCrossRefGoogle Scholar
  38. 38.
    Hassall E (for the International Pediatric Omeprazole Study Group): Omeprazole for maintenance therapy of erosive esophagitis in children [abstract]. Gastroenterology 2000, 118:A658.CrossRefGoogle Scholar
  39. 39.
    Li J, Zhao J, Hamer-Maansson JE, et al.: Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006, 28:419–427.PubMedCrossRefGoogle Scholar
  40. 40.
    Dohil R, Fidler M, Barshop B, et al.: Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis. Pediatr Nephrol 2005, 20:1786–1793.PubMedCrossRefGoogle Scholar
  41. 41.
    Katz PO, Anderson C, Khoury R, Castell DO: Gastrooesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998, 12:1231–1234.PubMedCrossRefGoogle Scholar
  42. 42.
    Pfefferkorn MD, Croffie JM, Gupta SK, et al.: Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. J Pediatr Gastroenterol Nutr 2006, 42:160–165.PubMedCrossRefGoogle Scholar
  43. 43.
    Farup C, Kleinman L, Sloan S, et al.: The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001, 161:45–52.PubMedCrossRefGoogle Scholar
  44. 44.
    Shaker R, Castell DO, Schoenfeld PS, Spechler SJ: Night-time heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003, 98:1487–1493.PubMedCrossRefGoogle Scholar
  45. 45.
    Canani RB, Cirillo P, Roggero P, et al.: Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006, 117:e817–e820.PubMedCrossRefGoogle Scholar
  46. 46.
    Guillet R, Stoll BJ, Cotten CM, et al.: Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006, 117:e137–e142.PubMedCrossRefGoogle Scholar
  47. 47.
    Saiman L, Ludington E, Pfaller M, et al.: Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J 2000, 19:319–324.PubMedCrossRefGoogle Scholar
  48. 48.
    Laheij RJ, Sturkenboom MC, Hassing RJ, et al.: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955–1960.PubMedCrossRefGoogle Scholar
  49. 49.
    Dial S, Delaney JA, Barkun AN, Suissa S: Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989–2995.PubMedCrossRefGoogle Scholar
  50. 50.
    Garcia Rodriguez LA, Ruigomez A, Panes J: Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007, 5:1418–1423.PubMedCrossRefGoogle Scholar
  51. 51.
    Orenstein SR, Hassall E: Infants and proton pump inhibitors: tribulations, no trials. J Pediatr Gastroenterol Nutr 2007, 45:395–398.PubMedCrossRefGoogle Scholar
  52. 52.
    Moore DJ, Tao BS, Lines DR, et al.: Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003, 143:219–223.PubMedCrossRefGoogle Scholar
  53. 53.
    Putnam PE: And the winner is ... unhappy coexistence. J Pediatr 2003, 143:147–148.PubMedCrossRefGoogle Scholar
  54. 54.
    Inadomi JM, Fendrick AM: PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol 2005, 3:208–215.PubMedCrossRefGoogle Scholar
  55. 55.
    Inadomi JM, Jamal R, Murata GH, et al.: Step-down management of gastroesophageal reflux disease. Gastroenterology 2001, 121:1095–1100.PubMedCrossRefGoogle Scholar
  56. 56.
    Inadomi JM, McIntyre L, Bernard L, Fendrick AM: Step-down from multiple-to single-dose proton pump inhibitors (PPIs): a prospective study of patients with hearburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003, 98:1940–1944.PubMedCrossRefGoogle Scholar
  57. 57.
    Ofman JJ, Gralnek IM, Udani J, et al.: The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999, 107:219–227.PubMedCrossRefGoogle Scholar
  58. 58.
    Boccia G, Manguso F, Miele E, et al.: Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? Am J Gastroenterol 2007, 192:1291–1297.CrossRefGoogle Scholar
  59. 59.
    Hassall E: Treatment interruptus: the need for withdrawal. Am J Gastroenterol 2007, 102:2108–2109.PubMedCrossRefGoogle Scholar
  60. 60.
    Fossmark R, Johnsen G, Johanessen E, Waldum HL: Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005, 21:149–154.PubMedCrossRefGoogle Scholar
  61. 61.
    Sandvik AK, Brenna E, Waldum HL: Review article: the pharmacological inhibition of gastric acid secretion—tolerance and rebound. Aliment Pharmacol Ther 1997, 11:1013–1018.PubMedCrossRefGoogle Scholar
  62. 62.
    Diaz DM, Gibbons TE, Heiss K, et al.: Antireflux surgery outcomes in pediatric gastroesophageal reflux disease. Am J Gastroenterol 2005, 100:1844–1852.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Division of GastroenterologyBritish Columbia Children’s HospitalVancouverCanada

Personalised recommendations